Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.

Emily H CastellanosAbigail OrlandoXinran MaRavi B ParikhGillian O'ConnellNeal J MeropolH James Hamrick Blythe J S Adamson

Published in: JCO oncology practice (2020)

OCM biomarker documentation and reporting requirements did not appear to increase the proportions of patients with aNSCLC who underwent testing or who received biomarker-guided therapy in OCM versus non-OCM practices.

Keyphrases

healthcare
palliative care
adverse drug
primary care
quality improvement
pain management
chronic pain
mesenchymal stem cells
cell therapy